Novo Nordisk to cap insulin prices in Minnesota settlement

Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.
Minnesota AG Reaches Another Insulin Price Cap Settlement
Keith Ellison said he's reached a deal with Danish pharmaceutical company Novo Nordisk to keep the cost of insulin at $35 a month.
Settlement secures $35-per-month insulin for all Minnesotans
The final settlement has been reached in the state's 2018 lawsuit filed against the three largest insulin manufacturers.
Minnesota AG announces insulin settlement
ST. PAUL, Minn. – Minnesota Attorney General Keith Ellison settled with insulin manufacturers Eli Lilly, Sanofi, and Novo Nordisk, guaranteeing that Minnesotans can purchase a month’s supply of Eli Lilly and Sanofi insulin products for just $35 for the next 5 years.
Minnesota insulin lawsuit: AG Ellison reaches settlement with Novo Nordisk
Minnesota Attorney General Keith Ellison announced on Monday that a settlement has been reached Novo Nordisk over the high cost of insulin.
Minnesota insulin cost lawsuit settlement caps price
The settlement means all Minnesotans can purchase insulin from the three biggest insulin manufacturers for just $35 per month.
All Minnesotans can now get insulin for just $35 a month
ST. PAUL, Minn. – All Minnesotans, whether they have insurance or not, will be able to buy insulin products for $35 a month for the next five years.
Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Attorney General secures $35 Novo Nordisk insulin for Minnesotans
The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Eli Lilly's SWOT analysis: stock poised for growth amid challenges
Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...